🟢 Scholar Rock is trading 11.89% up in pre-market after FDA approval of ISEMBYLD

Scholar Rock is trading 11.89% up in pre-market at $62.00 after the FDA approved ISEMBYLD on September 11, 2026, the company’s first approved treatment.

• It is authorized for adults and children aged two and older with spinal muscular atrophy receiving SMN2-targeted treatment.
• Commercial shipments are expected to begin shortly, supporting the strong pre-market reaction.
• Reuters and the company confirmed the approval and its clinical basis.